Treace Presents Updated ALIGN3D™ Interim Data and Latest Product Innovations at the 2023 ACFAS Annual Conference
PONTE VEDRA, Fla., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions) through its Lapiplasty® 3D Bunion Correction™ procedure today announced it will highlight new interim clinical data from the ALIGN3D™ study, and recent product innovations, at the 2023 American College of Foot and Ankle Surgeons (“ACFAS”) Annual Scientific Conference in Los Angeles, California.
- PONTE VEDRA, Fla., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions) through its Lapiplasty® 3D Bunion Correction™ procedure today announced it will highlight new interim clinical data from the ALIGN3D™ study, and recent product innovations, at the 2023 American College of Foot and Ankle Surgeons (“ACFAS”) Annual Scientific Conference in Los Angeles, California.
- The scientific poster titled, “Three Year Interim Analysis of a Five-Year Multicenter Study Assessing Radiographic and Patient Outcomes Following Triplanar Tarsometatarsal Arthrodesis with Early Weightbearing”,1 includes an interim analysis of 128 patients from the ALIGN3D™ study with at least 24 months of follow-up following the Lapiplasty® Procedure demonstrating:
Early return to weight bearing in a walking boot at an average 8.1 days;
92% and 90% improvement in walking/standing and social interaction patient-reported quality of life measures, respectively, using the Manchester-Oxford Foot Questionnaire (MOxFQ) through 36 months (n=41); and
John T. Treace, CEO, Founder and Board Member of Treace, said, “We are excited by the updated interim results from our ALIGN3D™ study showing high patient satisfaction with rapid return to weightbearing, low recurrence rates, and significant reduction in pain and patient reported outcome scores at 24 months following the Lapiplasty® procedure. - As a company focused on improving surgical outcomes for bunion patients, we are committed to reporting the long-term results of our novel Lapiplasty® procedure though this unique 5-year, multicenter study.”
During the ACFAS Conference, Treace will feature its current and next-generation technologies at its exhibit booth including the Micro-Lapiplasty™ and SpeedPlate™ systems, which are expected to commercialize later this year. - The Company will also be hosting Lapiplasty® and Adductoplasty® surgeon hands-on training labs featuring recently commercialized innovations, including the Lapiplasty® 3-n-1™ Guide, Lapiplasty® S4A Anatomic Plating Kit, and the SpeedRelease™ and TriTome™ tissue release instruments.